Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
=== Customer base === Officially, Sato says that its products are for business use only, for example for the use of food-processing industries or food-and-drink businesses (e.g. restaurant, café, sweets shop, bakery shop, etc.). Mainly, its products are to be used as food additives. Other than purposes for test sale, research, etc., it has never been sold for eating or drinking, including personal use or home use. In June 1982, Sato started production and sales for the drinking powdered alcohol, as test case. Its name is "powdered cocktail Alcock-Light cocktail" ("粉末カクテル 'アルコック・ライトカクテル' "). At least, during some years, it seems that had continued to test sales.
A study at Duke University found that decline in muscle strength as part of the aging process can be attributed to a decline in glutaminase, and that restoring it in the muscles of aged mice improved muscle function. A study at the University of California, San Francisco identified the accumulation of the protein FTL1 as the main driver of brain aging. An experiment found that removing it from the brains of elderly mice reversed age-related decline while introducing it into the brains of young mice immediately aged their brains. Researchers Tel Aviv University, Bar-Ilan University, and the National Institute on Aging reported reversing key signs of age-related decline in the livers of aged mice by boosting levels of Sirtuin 6. Researchers at Texas A&M University reported reversing signs of brain aging by using extracellular vesicles loaded with microRNAs to reduce inflammation by means of a nasal spray to bypass the blood–brain barrier. Two studies at Mass General Brigham found that the health of the thymus in adulthood is one of the strongest predictors of longevity, cardiovascular health, and cancer survival including response to immunotherapy in adulthood. Scientists at the Leibniz Institute on Aging identified declining levels of phosphatidylcholine as a driver of age-related mitochondrial dysfunction and loss of cellular energy. They found that boosting phosphatidylcholine resulted in more youthful mitochondrial performance in aging organisms.
Y chromosome One of two sex chromosomes present in organisms which use the XY sex-determination system. The Y chromosome is found only in males and is typically much smaller than its counterpart, the X chromosome.
In a light-emitting diode, the recombination of electrons and electron holes in a semiconductor produces light (infrared, visible or UV), a process called electroluminescence. The wavelength of the light depends on the energy band gap of the semiconductors used. Since these materials have a high index of refraction, design features of the devices, such as special optical coatings and die shape, are required to efficiently emit light. Unlike a laser, the light emitted from an LED is neither spectrally nor spatially coherent nor even highly monochromatic. Its spectrum is sufficiently narrow that it appears to the human eye as a pure (saturated) color. Also, it cannot approach the very high intensity characteristic of lasers.
==== Companion of the Order of St Michael and St George (CMG) ==== Jennifer Elizabeth Anderson, Director, Consular and Crisis, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to British Nationals Overseas. Zamir Nicholas Catasaras, Director General for Russia and Ukraine, Cabinet Office. For services to British Foreign Policy. Roger James Coventry, Criminal Justice Adviser. For services to Justice and Stability overseas. Colin Mark Evans, Director General, Foreign, Commonwealth and Development Office. For services to National Security. Dr Fiona Hill, Senior Fellow, Brookings Institution, Washington D.C., United States of America. For services to International Relations. Dr Rurik Miles Marsden, , Development Director, British Embassy Yangon, Myanmar. For services to International Development. Susanna Mary Davies Moorehead, lately Chair, Development Assistance Committee, The Organisation for Economic Co-operation and Development (OECD). For services to International Development and Diplomacy. Jane Anne Nelson, Director, Corporate Responsibility Initiative, Kennedy School of Government, Harvard University, United States of America. For services to Business and to Sustainability. Dr Sara Pantuliano, Chief Executive, ODI. For services to Peacebuilding, to Humanitarian Assistance and to International Development. Simon Penny, lately H.M. Trade Commissioner for the Middle East and Pakistan and H.M. Consul General to Dubai and the Northern Emirates. For services to International Trade and Investment.
Sources: en.wikipedia.org
Erin Shammel Baker is an American bioanalytical chemist specializing in developing ion mobility-mass spectrometry hybrid instruments for biological and environmental applications. Baker is an expert in the research of perfluoroalkyl and polyfluoroalkyl substances analysis.
{\displaystyle {\begin{aligned}{\frac {dM}{dt}}&=\Lambda -\delta M-\mu M\\[8pt]{\frac {dS}{dt}}&=\delta M-{\frac {\beta SI}{N}}-\mu S\\[8pt]{\frac {dI}{dt}}&={\frac {\beta SI}{N}}-\gamma I-\mu I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R\end{aligned}}}
Stephen Standfast is designated as his successor. 12 August – Green Party co-leader Chlöe Swarbrick is banned from Parliament for one week after criticising government MPs during a debate on the recognition of Palestine. 15 August: The Supreme Court of New Zealand rules that the Family Court used the wrong legal test to lock up a 20 year old autistic man for 20 years. The Supreme Court rules that riverbeds can be included in Māori customary marine title claims in the eastern Bay of Plenty. KiwiRail agrees to pay HD Hyundai Mipo a settlement of NZ$144 million for the New Zealand Government's 2023 cancellation of the Project iRex ferries. 16 August: Palestinian solidarity protests calling for an end to the Gaza war and sanctions against Israel are held in 20 cities and towns. Staff at Spring Hill Corrections facility quell a riot involving 11 prisoners. About 100 environmental protesters confront Resources Management Minister Shane Jones during his visit to Whangārei. The protesters were opposed to two fast-track projects including the construction of a marina in Waipiro Bay and proposed offshore sand mining in Bream Bay. Multiple trans-Tasman flights are disrupted by a technical fault in Airways New Zealand's main oceanic air control system. 18 August: KiwiRail's Interislander ferry Aratere is retired. Building and Construction Minister Chris Penk announces that the Government will introduce legislation to overhaul the building consent system.
In March 1916 (BR.23–BR.26), Robertson announced the results of a series of experiments that he and his assistant, Louis Adolph Ray, had conducted with the white mice — chosen as his "experimental animal" because of their "hardiness, rapid growth, smallness, and fecundity" (BR.23, p.366) — wherein the oral administration of tethelin, a "growth-controlling principle" (which they later described as "the ether-precipitable fraction of an alcoholic extract of the anterior lobe of the pituitary body"), produced precisely "the same effects on their growth" as those "which [had] accompan[ied] the [oral] administration of the whole tissue of the anterior lobe of the pituitary body" to his control group (BR.25, p.397). As Everitt (AE.2, p.63) notes — having distinguished (p.66) Robertson and Ray's "growth controlling principle" of the pituitary (BR.35) from Moon, et al.'s "growth stimulating principle" (HM.2) — it was not until the (1921) work of Herbert Evans and Joseph Long (HE.1; HE.2) that "[it was] conclusively proved that the pituitary contained a growth-stimulating hormone". Evans and Long also discovered that, whilst the oral administration of their "pituitary principle" had no effect, administration per medium of an intraperitoneal injection was effective: which led them to the conclusion that whatever the pituitary's 'active principle' might be, it was "digested in the alimentary canal".
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.